BACK TO TOP
KSE100
173,886.68
-1493.18
(-0.85%)
KSE100PR
51,443.57
-667.81
(-1.28%)
ALLSHR
104,193.89
-830.04
(-0.79%)
KSE30
50,762.89
-833.18
(-1.61%)
KMI30
248,644.12
-2588.32
(-1.03%)
BKTI
47,836.07
-497.73
(-1.03%)
OGTI
34,437.25
-371.76
(-1.07%)
KMIALLSHR
67,289.90
-536.64
(-0.79%)
PSXDIV20
79,697.94
-612.07
(-0.76%)
UPP9
62,851.34
-734.69
(-1.16%)
NITPGI
46,602.96
-491.25
(-1.04%)
NBPPGI
50,010.24
-553.45
(-1.09%)
MZNPI
31,212.45
-334.15
(-1.06%)
JSMFI
40,263.61
-236.99
(-0.59%)
ACI
22,170.62
-292.13
(-1.30%)
JSGBKTI
74,266.91
-765.99
(-1.02%)
HBLTTI
19,817.45
05-11-2026
488.27
(2.53%)
MII30
22,591.07
-220.02
(-0.96%)
BF Biosciences Limited
PHARMACEUTICALS
Rs.130.90
-1.72
(-1.30%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Fri, Nov 6, 2026 4:47 PM
REG
DFC
CSF
ODL
Open
132.10
High
132.10
Low
130.25
Volume
23,848
CIRCUIT BREAKER
119.36 — 145.88
DAY RANGE
130.25 — 132.10
52-WEEK RANGE ^
117.20 — 177.99
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
132.62
VAR
11.50
HAIRCUT
15.00
P/E Ratio (TTM) **
17.59
1-Year Change * ^
-14.65%
YTD Change * ^
-6.85%

No record found

Last update: Sun, Aug 30, 2026 3:51 AM
Open
0.00
High
0.00
Low
0.00
Close
0.00
Change
0.00%
LDCP
133.93
Volume
0
Total Trades
0
CIRCUIT BREAKER
120.54 — 147.32
DAY RANGE
0.00 — 0.00
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.

KEY PEOPLE
Muhammad Farhan RafiqCEO
Sebastian Martin FerrarassiChairperson
Abdur RehmanCompany Secretary
ADDRESS

197-A, The Mall, Rawalpindi, Pakistan

WEBSITE

www.bfbio.com

REGISTRAR

CDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi

AUDITOR

KPMG Taseer Hadi & Co. Chartered Accountants

Fiscal Year End

June

Equity Profile

Market Cap (000's)
11,562,833.42
Shares
88,333,334
Face Value
3.00
Free Float
26,500,000
Free Float
30.00%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Oct 30, 2026Transmission of Quarterly Financial Statements for the Period Ended 30-09-2026 View   PDF
Oct 28, 2026Annual Progress Report for the Year Ended June 30, 2026 View   PDF
Oct 28, 2026Financial Results for the Quarter Ended 30-09-2026 View   PDF
Oct 7, 2026Transmission of Annual Financial Statements for the Year Ended 30-06-2026 View   PDF
Sep 29, 2026Financial Results for the Year Ended 2026-06-30 View   PDF
DateTitleDocument
Oct 28, 2026Certified true copy of the resolutions passed in the Annual General Meeting of the Company View   PDF
Oct 20, 2026Board Meeting View   
Oct 7, 2026Notice of Annual General Meeting View   PDF
Oct 6, 2026Notice of Annual General Meeting prior to publication View   PDF
Sep 21, 2026Board Meeting View   
DateTitleDocument
Aug 20, 2026Material Information View   PDF
Jul 14, 2026Approval of Annual Budget for FY 2026-27 View   
Jun 9, 2026Appointment of Director to Fill Casual Vacancy View   PDF
Jun 2, 2026Intimation of Passing Away of Mrs. Akhter Khalid Waheed, Director and Founding CEO View   PDF
Jun 1, 2026Appointment of Director to Fill Casual Vacancy View   PDF

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
20262025
Sales9,461,2535,837,466
Profit after Taxation632,127447,147
EPS7.165.52
Q1 2027Q3 2026Q2 2026Q1 2026
Sales2,783,8862,135,4912,668,1252,432,294
Profit after Taxation184,882117,646187,782159,521
EPS2.091.332.131.81
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

2026202520242023
Gross Profit Margin (%)43.2039.1941.89
Net Profit Margin (%)6.687.6610.53
EPS Growth (%)29.71(9.36)
PEG0.67(3.27)

Payouts

Financial Reports